VivoSeq
Infectious Disease

Influenza

686

Pipeline Programs↗

91

Active Trials↗

90

Companies Involved↗

Influenza is a highly competitive landscape with 686 programs across 90 companies. The most active players are Inovio Pharmaceuticals, Sumitomo Pharma Co., Ltd., VA Pharma Limited Liability Company. 112 therapies are approved with 158 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

99/100

Pipeline Velocity

65/100

Mech. Concentration

8/100

Completion Rate

93/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Inovio Pharmaceuticals logo

Inovio Pharmaceuticals

4 programs

Phase 1S

Sumitomo Pharma Co., Ltd.

2 programs

Phase 1V

VA Pharma Limited Liability Company

2 programs

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 1L

LiteVax BV

1 program

Phase 1C

Colby Pharmaceutical Company

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical46

Influenza Virus Vaccine

Sanofi

Favipiravir

Appili Therapeutics Inc.

Menhibrix

Sanofi

Methotrexate

Alnylam Pharmaceuticals

Western Therapy

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Phase 1149

Pandemic Influenza Vaccine

Sinovac Biotech Co., Ltd

Fluzone Vaccine

Colby Pharmaceutical Company

Pembrolizumab

Merck & Co.

Nivolumab

Bristol-Myers Squibb

Bimekizumab

UCB

Phase 2221

Mrna-1010

Moderna

Atorvastatin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Chloroquine

Sanofi

Active Comparator

Moderna

Infanrix

GSK

Phase 3158

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Nitazoxanide

Romark Laboratories L.C.

Celecoxib

Philadelphia Eye Associates

Imiquimod

Bausch Health Americas, Inc.

IVACFLU-S

Vietnam Military Medical University

Approved112

Acetylcysteine

Arbor Pharmaceuticals, Inc.

Amantadine

Grupo Espanol de Tumores Neuroendocrinos

Hepatitis a Vaccine

Sanofi

Acetaminophen

Kenvue Brands

Baloxavir Marboxil

Roche

Analysis

Modality Breakdown

65%

Vaccine

418 of 640 classified programs — the dominant modality here.

35%ALL OTHERSSmall molecule19530%RNA therapy183%Monoclonal antibody6<1%Protein / enzyme2<1%Cell therapy1<1%

Vaccine leads; the ring shows all 640 classified programs, each share of the total. Modality classified for 100% of 1,054 pipeline programs.

Analysis

Trial Status

1,400

clinical trials

Completed1,144 · 82%
Unknown status79 · 6%
Terminated54 · 4%
Recruiting41 · 3%
Active, not recruiting35 · 3%
Withdrawn28 · 2%
Other19 · 1%

Clinical Trials

Trial Activity

1400 trials

Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT06863142·45 enrolled
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts
Recruiting·Roche logoRoche·Phase 3·NCT06094010·750 enrolled
The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study
Recruiting·TThe University of Hong Kong·Phase 4·NCT07240922·600 enrolled
High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT05947071·312 enrolled
Intradermal Influenza Vaccination
Recruiting·YYale University·Phase 1·NCT06067555·249 enrolled
Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT07111078·56 enrolled
Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.
Recruiting·VValenta Pharm JSC·Phase 2·NCT07420985·300 enrolled
A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza
Recruiting·UUniversity of Oxford·Phase 2·NCT05648448·3,000 enrolled
B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults
Recruiting·UUniversity of Alabama at Birmingham·Phase 4·NCT04101838·50 enrolled
Study of Immune Responses to Influenza Vaccination
Recruiting·UUniversity of Pennsylvania·Phase 4·NCT03346772·75 enrolled
Covid-19 and Influenza Oral Vaccine Study
Recruiting·VVaxine Pty Ltd·Phase 1·NCT06355232·100 enrolled
Clinical Trial Evaluating the Efficacy and Safety of Dexamethasone Compared to Placebo in Patients With Severe Influenza
Recruiting·IInstituto de Investigación Sanitaria y Biomédica de Alicante·Phase 3·NCT06528444·42 enrolled
Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine
Recruiting·CanSino Biologics Inc. logoCanSino Biologics Inc.·Phase 1·NCT07203755·260 enrolled
A Study to Learn About mRNA Vaccines Against Influenza in Adults
Recruiting·Pfizer logoPfizer·Phase 2·NCT07431853·770 enrolled
Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults
Recruiting·UUniversity of Pennsylvania·Phase 4·NCT05108818·700 enrolled
Page 1 of 94

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)